Company Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF.
It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs.
The company was incorporated in 2015 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Marcio De'Souza |
Contact Details
Address: 99 High Street, 30th Floor Boston, Massachusetts 02110 United States | |
| Phone | 617 300 8460 |
| Website | praxismedicines.com |
Stock Details
| Ticker Symbol | PRAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001689548 |
| CUSIP Number | 74006W108 |
| ISIN Number | US74006W2070 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marcio Silva De'Souza M.B.A. | President, Chief Executive Officer and Director |
| Timothy Edwin Kelly | Chief Financial Officer and Treasurer |
| Alex Nemiroff J.D. | General Counsel and Secretary |
| Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder and Chief Scientific Officer |
| Lauren Mastrocola | Vice President of Finance and Principal Accounting Officer |
| Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer |
| Alex Kane | Vice President of Investor Relations and Corporate Communications |
| Kelly McCue | Chief People Officer |
| Alyssa J. S. Wyant | Chief Regulatory and Quality Officer |
| Megan T. Sniecinski | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 144 | Filing |
| Nov 14, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |